Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and
oral anticoagulation therefore is the essential part of AF management to reduce the risk of …

Background Non‐vitamin K antagonist oral anticoagulants (NOAC s) are broadly preferable
to vitamin K antagonists (VKA s) for stroke prevention in non‐valvular atrial fibrillation (AF) …

Direct oral anticoagulants (DOACs) are a favored treatment to prevent stroke in patients with
atrial fibrillation (AF). There are limited data concerning the efficacy and safety of DOACs in …

Aims The aim of the present meta-analysis was to evaluate the efficacy and safety of non-
vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in elderly patients with …

Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …

The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

The efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial
fibrillation (AF) with coronary or peripheral artery disease (CAD or PAD) remain largely …

Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …